There is a stage shift for non-small cell lung cancer that could substantially confound the evaluation of newer therapeutics and mortality outcomes. This study found that the stage shift from later to earlier stage disease over the last decade was associated with improved mortality among people with lung cancer.
This article was originally published in JAMA Network Open.